Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Study of BDC-1001 as a Single Agent and in Combination With Nivolumab in Patients With Advanced HER2-Expressing Solid Tumors

Next Previous
Trial Profile

Phase 1/2 Study of BDC-1001 as a Single Agent and in Combination With Nivolumab in Patients With Advanced HER2-Expressing Solid Tumors

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 03 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Trastuzumab imbotolimod (Primary)
  • Indications Advanced breast cancer; Biliary cancer; Cancer metastases; Cervical cancer; Colon cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; HER2 positive breast cancer; Lung cancer; Oesophageal cancer; Ovarian cancer; Rectal cancer; Salivary gland cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Bolt Biotherapeutics

Most Recent Events

  • 12 Nov 2024 According to a Bolt Biotherapeutics media release, results from this Phase 1 dose-escalation trial of BDC-1001 Presented at SITC 39th Annual Meeting.
  • 07 Nov 2024 Results presented in the Bolt Biotherapeutics Media Release.
  • 07 Nov 2024 According to a Bolt Biotherapeutics media release, Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 will be presented at SITC 39th Annual Meeting being held in Houston, Texas from November 9, 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top